India, Jan. 28 -- Global pharma major Lupin and Avas Pharmaceuticals SRL have announced the launch of Lupin's orphan drug NaMuscla (mexiletine) in Italy. Avas will commercialise NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. NaMuscla is the first and only licensed product for this indication.

NDM disorders are a group of rare, inherited neuromuscular disorders which is characterised by the inability to relax muscles following voluntary contraction. NaMuscla reduces myotonia symptoms in people with NDM, resulting in a significant improvement in quality of life and other functional and clinical outcomes for patients. NaMuscla, which has been designated orphan drug status, received...